Juvenile Arthritis News

Reducing steroids in favor of more targeted therapies can minimize organ damage in pediatric systemic lupus erythematosus, according to data presented at EULAR 2024 Congress.

Converting an empty building into an information hub and social media campaigns were among the “innovative” strategies employed by a U.K.-based patient organization to raise awareness of juvenile arthritis, according to EULAR.

Caregivers of pediatric rheumatology patients transitioning to adult care reported a “lack of clear information” on the necessary procedures, according to data presented at the EULAR 2024 Congress.

The FDA has approved the interleukin-6 inhibitor Kevzara for the treatment of polyarticular juvenile idiopathic arthritis, according to a press release from Regeneron Pharmaceuticals and Sanofi.

Pediatric rheumatology patients could be considered ready to transfer to adult care if they score greater than 4 on the Transition Readiness Assessment Questionnaire, according to data published in Rheumatology.

The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.

New definitions of remission specific to childhood systemic lupus erythematosus promote cessation of corticosteroids and could enable combined child-adult treat-to-target studies, according to an analysis published in Clinical Immunology.

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

The FDA has approved a Benlysta autoinjector for children aged 5 years and older with systemic lupus erythematosus, enabling at-home administration for the first time, according to a press release from the manufacturer.

The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.